Search research articles
Contact Us
Filters
Showing results (11-20 of 204) with videos related to
Page
of 21
Sort By:
Cancer
|
April 4, 2003
Overview of bladder cancer trials in the European Organization for Research and Treatment
Ronald de Wit,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2015
Primum Non Nocere: Of Course! But How?
Jan Oldenburg, Ronald de Wit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
Controversies in the management of clinical stage I testis cancer
Ronald de Wit, Karim Fizazi
Critical Reviews in Oncology/Hematology
|
February 27, 2003
Overview of gemcitabine triplets in metastatic bladder cancer
Ronald de Wit, Joaquim Bellmunt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Optimal management of clinical stage I testis cancer: one size does not fit all
Ronald de Wit, George J Bosl
European Urology
|
August 6, 2013
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer
John M Fitzpatrick, Ronald de Wit
Seminars in Urologic Oncology
|
August 29, 2002
Editorial: the coming revolution in the treatment of prostate cancer patients
Daniel P Petrylak, Ronald de Wit
European Urology
|
November 21, 2020
Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer
Ronald de Wit, Bertrand Tombal, Stephen Freedland
European Urology
|
October 18, 2016
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033
Robert J van Soest, Ronald de Wit
European Urology
|
August 22, 2016
Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?
Martijn Lolkema, Reno Debets, Ronald de Wit
Page
of 21
Search research articles
Search
Showing results (11-20 of 204) with videos related to
Sort By:
Page
of 21
Cancer
|
April 4, 2003
Overview of bladder cancer trials in the European Organization for Research and Treatment
Ronald de Wit,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2015
Primum Non Nocere: Of Course! But How?
Jan Oldenburg, Ronald de Wit
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
Controversies in the management of clinical stage I testis cancer
Ronald de Wit, Karim Fizazi
Critical Reviews in Oncology/Hematology
|
February 27, 2003
Overview of gemcitabine triplets in metastatic bladder cancer
Ronald de Wit, Joaquim Bellmunt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Optimal management of clinical stage I testis cancer: one size does not fit all
Ronald de Wit, George J Bosl
European Urology
|
August 6, 2013
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer
John M Fitzpatrick, Ronald de Wit
Seminars in Urologic Oncology
|
August 29, 2002
Editorial: the coming revolution in the treatment of prostate cancer patients
Daniel P Petrylak, Ronald de Wit
European Urology
|
November 21, 2020
Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer
Ronald de Wit, Bertrand Tombal, Stephen Freedland
European Urology
|
October 18, 2016
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033
Robert J van Soest, Ronald de Wit
European Urology
|
August 22, 2016
Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?
Martijn Lolkema, Reno Debets, Ronald de Wit
Page
of 21